PHARMATHER INC.
  • COMPANY
    • Management
    • Board of Directors
  • RESEARCH
    • Pipeline
    • MN Delivery
    • KETABET
    • panaceAI
    • Patents
  • Investors
  • News
  • Contact
  • COMPANY
    • Management
    • Board of Directors
  • RESEARCH
    • Pipeline
    • MN Delivery
    • KETABET
    • panaceAI
    • Patents
  • Investors
  • News
  • Contact

We're on a path to deliver​

CSE: PHRM | ​OTCQB: PHRRF

INVESTOR DECK

Press Releases

February 23, 2021
​PharmaTher Announces Research Collaboration with Terasaki Institute for Novel Microneedle Delivery of Psychedelic Pharmaceuticals
February 17, 2021
PharmaTher Announces Sale of Psilocybin Program
February 4, 2021
​PharmaTher Announces Successful Completion of Pre-IND Meeting with FDA for the Clinical Development of Ketamine in the Treatment of Parkinson's Disease
February 1, 2021
​PharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Delivery Ketamine

Register for our latest developments and events.

SIGN UP

CONNECT WITH US

Publicly-traded on the CSE: PHRM and OTCQB: PHRRF
© COPYRIGHT 2021.  PharmaTher Inc.   ALL RIGHTS RESERVED.